Sarepta Therapeutics (NASDAQ: SRPT)
Sarepta Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sarepta Therapeutics Company Info
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
News & Analysis
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
The upcoming regulatory decision on its latest drug could be big.
Is It Too Late to Buy Sarepta Therapeutics Stock?
The company's hyperfocus on its core area could continue to be highly lucrative.
Why Sarepta Therapeutics Stock Is Soaring Today
The biotech just scored a big FDA win with an even bigger one potentially coming by June.
2 Magnificent Growth Stocks to Buy With $500
No need to break the bank to invest in promising stocks.
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Bad news for one player does not always equal good news for another.
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
It's always tough to be compared to a giant.
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
One pundit feels there is solid potential in one of the company's more recently approved drugs.
Valuation
Podcast Episodes
One Biotech Crashes, the Other Skyrockets -- Here's Why
Hit-or-miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy. Meanwhile, a disappointing data readout stops one vaccine maker in its tracks.
Digging Into Disappointment: What Investors Need To Know About Sarepta and Gilead Sciences' "Bad News"
Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales.
Earnings Transcripts
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2023.
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2023.
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2023.
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.